About
Axovia Therapeutics develops gene therapies using AAV9 vectors to deliver functional copies of faulty BBS1 genes, targeting genetic ciliopathies like Bardet-Biedl Syndrome to prevent blindness and reverse obesity.
Explore Axovia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.